Anti-gp240 antigen Immunocytokine, scFv (scFvMEL)-GrB (ACFP-SH067)
This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-gp240 antigen scFv to GrB. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the gp240 antigen as well as the biological activity of GrB. The GrB/scFvMEL fusion construct demonstrates impressive antitumor activity and enhances the sensitivity of human melanoma cells to chemotherapy. This immunocytokine was designed for treating melanoma.
Specifications
- Target
- gp240 antigen
- Molecule Class
- scFv-GrB
- Species Reactivity
- Human
- Host
- Mouse
- Expression Host
- CHO
- Clone
- ZME-018 (scFvMEL)
- Related Disease
- Melanoma
- Cytokines 1
- GrB
- Cytokines 1 Description
- The serine protease granzyme B (GrB) is integrally involved in apoptotic cell death induced in target cells upon their exposure to the contents of lysosome-like cytoplasmic granules (or cytolytic granules) found in cytotoxic T-lymphocytes (CTL) and natural killer (NK) cells. Cytotoxic lymphocyte granules contain perforin, a pore-forming protein, and a family of serine proteases, termed granzymes.
- Cytokine 1 Species
- Human
- Applications
- This product can be used therapeutically to deliver biologically active ligands to a desired tissue.
Target
- Alternative Names
- gp240 antigen
For lab research use only, not for diagnostic, therapeutic or any in vivo human use.
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email: